
S23 Powder Sarms For Bodybuilding CAS:1010396-29-8
S23 SARM powder represents a specific, research-grade chemical entity increasingly discussed within experimental bodybuilding circles. Understanding its profile requires moving beyond generic descriptions and delving into its unique molecular characteristics and the complex realities of its potential applications. This analysis aims for originality by focusing on nuanced pharmacological aspects and under-discussed practical considerations.
What is S23 SARM Powder?
●Core Identity: S23 (developmental code name) is classified as a Selective Androgen Receptor Modulator (SARM). Its core mechanism involves selectively binding to and activating androgen receptors (AR), primarily in skeletal muscle and bone tissue. Unlike anabolic steroids, which are steroidal molecules derived from testosterone, SARMs like S23 are non-steroidal compounds designed for tissue selectivity.
●Powder Form: The raw S23 material exists as a fine, crystalline powder. This is the pure chemical entity, typically synthesized in laboratories adhering to research chemical standards (though quality control varies significantly in unregulated markets). It lacks formulation (like binding agents, fillers, or flavorings found in capsules/liquids), requiring researchers to precisely measure and solubilize it for experimental use (commonly in solvents like PEG-400 or ethanol).
●Research Status: Crucially, S23 remains an investigational compound. It has never been approved for human medical or veterinary use by any major regulatory body (FDA, EMA, etc.). All available data stems from preclinical studies (animal models) and uncontrolled, anecdotal reports from the grey-market bodybuilding community. Its development history is murky, with initial patents suggesting potential applications in muscle wasting and osteoporosis, but clinical development stalled.


Features & Pharmacological Profile (Beyond Basics):
●High Binding Affinity & Anabolic Ratio: Preclinical data suggests S23 possesses exceptionally high binding affinity for the androgen receptor (AR), often reported as higher than many other well-known SARMs and even approaching some anabolic steroids. This theoretically translates to potent anabolic signaling.
●Tissue Selectivity (Theoretical): The promise of SARMs lies in selectivity – activating ARs in muscle and bone while sparing organs like the prostate, liver, and sebaceous glands associated with androgenic side effects. However, S23's high potency and full agonism raise questions about the degree of selectivity achievable at doses sought for significant muscle gain. Evidence suggests its selectivity profile might be less favorable than earlier-generation SARMs like Ostarine or Ligandrol, particularly at higher doses.
●Potential Androgenic Activity: Unlike some SARMs designed as partial agonists, S23 appears to act as a full agonist at the AR. Combined with its high affinity, this significantly increases the risk of triggering androgenic side effects (acne, accelerated hair loss in predisposed individuals, potential prostate impact) as doses escalate, blurring the line between its effects and traditional steroids.
●Metabolic Stability: S23 exhibits relatively good metabolic stability compared to some other SARMs, contributing to its longer half-life. This stability reduces rapid breakdown but may also prolong potential suppressive effects on the HPTA (Hypothalamic-Pituitary-Testicular Axis).
●Anabolic to Androgenic Ratio (Preclinical): Early animal studies suggested a favorable anabolic (muscle-building) to androgenic (masculinizing) ratio compared to testosterone. However, translating this ratio directly to humans, especially at supra-physiological doses common in bodybuilding experimentation, is highly speculative and likely inaccurate. The high potency often overrides the theoretical selectivity in practice.
Applications in Experimental Bodybuilding Contexts:
Within the unregulated research/underground bodybuilding sphere, S23 powder is explored for:
●Muscle Hypertrophy Acceleration: Its potent AR activation is theorized to significantly upregulate protein synthesis pathways and satellite cell activity, potentially leading to rapid lean mass accrual, often reported as more "dry" or dense gains compared to some steroids.
●Enhanced Fat Loss/Metabolism: Androgen receptor activation influences metabolic rate and nutrient partitioning. Users report S23 facilitates fat loss while preserving or building muscle during caloric deficits ("recomp" phases) or lean bulks.
●Increased Strength & Performance: Potent anabolic signaling directly correlates with neural drive and myofibrillar density, frequently yielding substantial strength increases.
●Bone Density Support: While less relevant to short-term bodybuilding goals, the AR activation in bone is a theoretical benefit, though long-term human data is nonexistent.
●"Hardening" Effect: Many anecdotal reports describe a distinct "hard," vascular, and grainy appearance to the muscles, attributed to low water retention and direct effects on muscle tissue.
Purported Benefits (With Critical Caveats):
●Potency: Often cited as the most potent readily available SARM, offering significant potential for muscle and strength gains.
●Reduced Estrogenic Side Effects: As a non-aromatizable compound (doesn't convert to estrogen), it avoids gynecomastia, significant water retention, and estrogen-related blood pressure spikes associated with aromatizing steroids.
●Theoretical Organ Sparing (At Lower Doses): The design principle suggests less liver toxicity than oral steroids and reduced impact on the prostate compared to equivalent anabolic doses of testosterone. However, high doses likely diminish this advantage significantly.
●Oral Bioavailability: Unlike many injectable steroids, S23 powder is active when ingested orally after proper solubilization.
●"Dry" Gains: Typically promotes lean tissue accumulation with minimal subcutaneous water retention.
Dosage, Cycle Structure & Half-Life: Navigating Uncertainty
●Dosage (Highly Speculative & Risky): Due to the lack of clinical data, dosing is extrapolated from animal studies and uncontrolled human reports. This is inherently dangerous.
○Powder Handling: Requires meticulous precision scales (0.001g accuracy) and sterile technique for solubilization. Errors are common and dangerous.
○Reported Range: Anecdotal dosages typically range from 10mg to 30mg per day. Many users start at the lower end (10-15mg) and assess tolerance. Doses above 20mg/day are frequently associated with significant side effects and suppression. There is no established safe or effective human dose.
●Cycle Length: Cycles are typically shorter than with milder SARMs due to potency and suppression. Common ranges are 6 to 8 weeks. Extending beyond 8 weeks drastically increases the risk of severe suppression and adverse effects. Longer cycles (10-12 weeks) are occasionally reported but carry substantially higher risks.
●Half-Life: S23 has a relatively long half-life for a SARM, estimated at approximately 24 hours. This allows for once-daily dosing. Its persistence also means effects (and suppression) linger after cessation, influencing Post-Cycle Therapy (PCT) timing.
Post-Cycle Therapy (PCT) - Imperative but Complex:
The potent suppression of natural testosterone production caused by S23 makes PCT a critical consideration, not an optional one. Ignoring PCT risks prolonged low testosterone (low T) with debilitating symptoms (fatigue, depression, libido loss, muscle loss).
●Why PCT is Crucial: S23's full AR agonism and long half-life lead to significant negative feedback on the HPTA, shutting down endogenous testosterone synthesis.
●Timing: PCT should commence after S23 has sufficiently cleared the system. Given the ~24-hour half-life, waiting 5-7 days after the last dose is generally recommended before starting PCT agents. Starting too early is ineffective; starting too late prolongs the hypogonadal state.
●Common PCT Components (Based on Anecdotal Protocols):
○SERMs (Selective Estrogen Receptor Modulators): The cornerstone.
◇Tamoxifen (Nolvadex): Often used at 20-40mg/day for 2-4 weeks, then 10-20mg/day for 2-4 weeks. Blocks estrogen receptors in the pituitary, stimulating LH/FSH production.
◇Clomiphene (Clomid): Used at 25-50mg/day for 4-6 weeks. Similar mechanism to Tamoxifen but can have more pronounced mood side effects. Often used alone or combined with Tamoxifen.
○hCG (Human Chorionic Gonadotropin) - Optional/Controversial: Mimics LH, directly stimulating the testes to produce testosterone during the cycle or in the gap before SERMs start ("blast"). Use is debated due to potential desensitization and estrogenic side effects. Not strictly necessary for SARM-only cycles but sometimes incorporated. Not a standalone PCT.
●PCT Duration: Typically 4-6 weeks, depending on the compounds used, dosages, and individual recovery response. Blood work (testosterone, LH, FSH) pre-cycle, mid-cycle (optional), and post-PCT is the only reliable way to gauge recovery. Guessing is perilous.
Significant Risks & Under-Discussed Realities:
●Profound HPTA Suppression: S23 is arguably the most suppressive SARM available. Recovery without proper PCT is slow and symptomatic. Even with PCT, full recovery isn't guaranteed and can take months.
●Androgenic Side Effects: High doses reliably cause acne (often severe), accelerated male pattern baldness in predisposed individuals, increased body hair growth, and potential aggression/mood swings. Prostate impacts are a serious theoretical concern.
●Cardiovascular Risks: All potent AR agonists can negatively impact cholesterol profiles (lowering HDL "good" cholesterol, potentially raising LDL). S23 is no exception. Long-term cardiovascular risks are unknown but concerning.
●Liver Strain: While likely less hepatotoxic than methylated oral steroids, significant liver enzyme elevations have been reported with S23 use. Regular liver function monitoring is essential but often neglected.
●Vision Disturbances: Anecdotal reports of mild to moderate vision changes (blurriness, difficulty focusing, "yellow tint") exist, though less common than with some other compounds. The mechanism is unclear and potentially irreversible.
●Purity & Legality: Powder sourcing is unregulated. Risks include mislabeling, contamination (heavy metals, solvents), or substitution with cheaper/unknown compounds. S23 is a Schedule III controlled substance in the US (2018 SARM Control Act) and illegal for human consumption in many countries. Possession carries legal risk.
●Lack of Long-Term Safety Data: The complete absence of human trials means the long-term consequences of S23 use on organs, fertility, and cancer risk are entirely unknown. This is perhaps the most significant risk.
Clinical Data
| Trade names | S23 |
|
CAS |
1010396-29-8 |
|
Molar mass |
416.76 |
|
MF |
C18H13ClF4N2O3 |
|
Purity |
Above 98% |
|
Apprarance |
White Cyrstalline Powder |
Any needs, please contact us
Email: Jasonraws106@gmail.com
WhatsApp: +86-15572565525
Telegram: +86-15871669785

Conclusion: A High-Potency, High-Risk Experimental Compound
S23 SARM powder is not a mild supplement; it's a potent, research-grade androgen receptor agonist with significant anabolic potential matched by substantial biological risks. Its high binding affinity and full agonism make its effects and side-effect profile closer to traditional anabolic steroids than to milder SARMs. The allure of rapid, "dry" gains must be weighed against the near-certainty of significant testosterone suppression requiring structured PCT, a high incidence of androgenic side effects, and completely unknown long-term health consequences.
Hot Tags: s23 powder sarms for bodybuilding cas:1010396-29-8, China s23 powder sarms for bodybuilding cas:1010396-29-8 manufacturers, suppliers, factory, SR9009, SR9009 Hormone and Metabolic Regulators, AC-262, Sarms S 23 selective androgen receptor modulator, GW501516 Ergogenic performance enhancing, GW0742 Hormone and Metabolic Regulators
